e-therapeutics is integrating computational power and biology to accelerate the discovery of life-transforming RNAi medicines.
We use our RNAi chemistry platform, GalOmic™, to generate specific, potent, and long-acting siRNA therapeutics for effective silencing of novel gene targets in the liver. The discovery of our GalOmic™ therapies is enhanced by integration of computational and AI approaches throughout the R&D process. Our cutting-edge HepNet™ computational platform allows us to discover better medicines faster through generation of novel insights and increased automation across all stages of drug discovery. HepNet™ encompasses an extensive hepatocyte-specific knowledgebase and a suite of advanced AI-driven approaches which enable identification of novel gene targets, rapid target-indication assessment, and predictive in silico siRNA design.
Leveraging the combined capabilities of HepNet™ and GalOmic™, we are progressing a pipeline of novel, highly differentiated GalOmic™ therapies across a variety of indications with high unmet need. Our therapeutic pipeline spans diseases within cardiometabolic disease, haematology, and ophthalmology, showcasing the breadth of diseases that can be treated with our liver-targeted therapies. We are currently progressing our GalOmic™ therapies towards the clinic with our most developed assets, ETX-312 for MASH and ETX-407 for dry AMD, at the IND-enabling stage.
